Education
About Us
Working with TipRanks
Follow Us
Outlook Therapeutics (OTLK)
NASDAQ:OTLK
OTLK Stock Chart & Stats
$2.17
-$0.17(-7.61%)
At close: 4:00 PM EST
$2.17
-$0.17(-7.61%)
Day’s Range― - ―
52-Week Range$0.79 - $3.39
Previous CloseN/A
Volume358.39K
Average Volume (3M)4.05M
Market Cap
$87.95M
Enterprise Value$84.93M
Total Cash (Recent Filing)$8.90M
Total Debt (Recent Filing)$34.70M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Dec 18, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding44,419,530
10 Day Avg. Volume2,169,596
30 Day Avg. Volume4,053,879
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-1.36
Price to Sales (P/S)0.00
P/FCF Ratio-1.44
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue50.69
Enterprise Value/Gross Profit77.72
Enterprise Value/Ebitda-1.76
Forecast
1Y Price Target
$4.50Price Target Upside107.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial FocusThe commercialization of Lytenava (ONS-5010) in Europe, particularly Germany, is the company's focus.
European LaunchThe focus is expected to shift to the ongoing European launch, which is in the early stages, while pricing negotiations continue.
Market ExpansionExpansion into other European countries, starting in Austria and the Netherlands, could drive further growth.
Bears Say
Development RiskONS-5010 is the company's sole active development program, presenting a risk if it fails.
Financial StabilityFinancing continues to be a major overhang on the name; with cash guidance only for the next 3 months, there are serious doubts on the company's ability to get ONS-5010 approved in the U.S.
Regulatory ChallengesThe FDA issued a CRL for the BLA resubmission of ONS-5010 in wet AMD, requiring additional evidence of efficacy for approval.
Outlook Therapeutics News
OTLK FAQ
What was Outlook Therapeutics’s price range in the past 12 months?
Outlook Therapeutics lowest stock price was $0.79 and its highest was $3.39 in the past 12 months.
What is Outlook Therapeutics’s market cap?
Outlook Therapeutics’s market cap is $87.95M.
When is Outlook Therapeutics’s upcoming earnings report date?
Outlook Therapeutics’s upcoming earnings report date is Dec 18, 2025 which is in 2 days.
How were Outlook Therapeutics’s earnings last quarter?
Outlook Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.352 by -$0.088.
Is Outlook Therapeutics overvalued?
According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued.
Does Outlook Therapeutics pay dividends?
Outlook Therapeutics does not currently pay dividends.
What is Outlook Therapeutics’s EPS estimate?
Outlook Therapeutics’s EPS estimate is -0.26.
How many shares outstanding does Outlook Therapeutics have?
Outlook Therapeutics has 44,419,530 shares outstanding.
What happened to Outlook Therapeutics’s price movement after its last earnings report?
Outlook Therapeutics reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.352. Following the earnings report the stock price went up 14.085%.
Which hedge fund is a major shareholder of Outlook Therapeutics?
Currently, no hedge funds are holding shares in OTLK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Outlook Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.50 (107.37% Upside)
$4.50 (107.37% Upside)
Blogger Sentiment
Bullish
OTLK Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 151.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.9%
Last 30 Days ▲ 11.7%
Last 30 Days ▲ 11.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-52.45%
Trailing 12-Months
Company Description
Outlook Therapeutics
Outlook Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody therapies. The company is primarily engaged in the research and development of therapeutics in the field of ophthalmology. Its leading product candidate is ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation designed for use in treating wet age-related macular degeneration (AMD) and other retinal diseases.
OTLK Stock 12 Month Forecast
Average Price Target
$4.50
▲(107.37% Upside)
Technical Analysis
Ownership Overview
31.77% Insiders
3.29% Mutual Funds
0.48% Other Institutional Investors
61.68% Public Companies and Individual Investors